The Citing articles tool gives a list of articles citing the current article. The citing articles come from EDP Sciences database, as well as other publishers participating in CrossRef Cited-by Linking Program. You can set up your personal account to receive an email alert each time this article is cited by a new article (see the menu on the right-hand side of the abstract page).
This article has been cited by the following article(s):
Synthetic product-based approach toward potential antileishmanial drug development
Rohit Pal, Ghanshyam Teli, Md Jawaid Akhtar and Gurubasavaraja Swamy Purawarga Matada European Journal of Medicinal Chemistry 263 115927 (2024) https://doi.org/10.1016/j.ejmech.2023.115927
Étude de la sélection de bactéries résistantes aux antibiotiques dans les élevages bovins ayant recours à la paromomycine contre la cryptosporidiose du veau
Romane Dubost, Clara Bourel Conroy, Frederic Lebœuf and Yves Millemann Le Nouveau Praticien Vétérinaire élevages & santé 16(59) 80 (2024) https://doi.org/10.1051/npvelsa/2025030
In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania
Estela Melcón-Fernández, Giulio Galli, Rafael Balaña-Fouce, Nerea García-Fernández, María Martínez-Valladares, Rosa M. Reguera, Carlos García-Estrada and Yolanda Pérez-Pertejo Tropical Medicine and Infectious Disease 9(2) 30 (2024) https://doi.org/10.3390/tropicalmed9020030
Yash Gupta, Steven Goicoechea, Jesse Vance, Andres P. Trujillo, Akankcha Alok, Samuel K. Kwofie, Brijesh Rathi, Ravi Durvasula and Prakasha Kempaiah 329 (2023) https://doi.org/10.1007/978-981-19-9605-4_16
Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages
Jabson Herber Profiro de Oliveira, Igor Eduardo Silva Arruda, José Izak Ribeiro de Araújo, et al. Expert Opinion on Therapeutic Patents 32(1) 89 (2022) https://doi.org/10.1080/13543776.2021.1970746
Leishmaniasis: where are we and where are we heading?
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
Ana Isabel Olías-Molero, Concepción de la Fuente, Montserrat Cuquerella, Juan J. Torrado and José M. Alunda Microorganisms 9(12) 2500 (2021) https://doi.org/10.3390/microorganisms9122500
Pathogenesis, Treatment and Prevention of Leishmaniasis
Targeting the Trypanothione Reductase of Tissue-Residing Leishmania in Hosts’ Reticuloendothelial System: A Flexible Water-Soluble Ferrocenylquinoline-Based Preclinical Drug Candidate
Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs
Alberto Rastrojo, Raquel García-Hernández, Paola Vargas, et al. International Journal for Parasitology: Drugs and Drug Resistance 8(2) 246 (2018) https://doi.org/10.1016/j.ijpddr.2018.04.002
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress
Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani
Aditya Verma, Vasundhra Bhandari, Deepak Kumar Deep, et al. International Journal for Parasitology: Drugs and Drug Resistance 7(3) 370 (2017) https://doi.org/10.1016/j.ijpddr.2017.10.004
Antimicrobial Drug Resistance
Goutam Mandal, Vaidya Govindarajan, Mansi Sharma, Hiranmoy Bhattacharjee and Rita Mukhopadhyay Antimicrobial Drug Resistance 649 (2017) https://doi.org/10.1007/978-3-319-46718-4_42
Antileishmanial activity of novel indolyl–coumarin hybrids: Design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction
Jaiprakash N. Sangshetti, Firoz A. Kalam Khan, Abhishek A. Kulkarni, et al. Bioorganic & Medicinal Chemistry Letters 26(3) 829 (2016) https://doi.org/10.1016/j.bmcl.2015.12.085
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
James S. McCarthy, Glenn W. Wortmann and Louis V. Kirchhoff Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 510 (2015) https://doi.org/10.1016/B978-1-4557-4801-3.00041-2
In Vivo
Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model
Antileishmanial drug discovery: comprehensive review of the last 10 years
Jaiprakash N. Sangshetti, Firoz A. Kalam Khan, Abhishek A. Kulkarni, Rohidas Arote and Rajendra H. Patil RSC Advances 5(41) 32376 (2015) https://doi.org/10.1039/C5RA02669E
Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum
Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis
M. J. Corral, D. R. Serrano, I. Moreno, et al. Journal of Antimicrobial Chemotherapy 69(12) 3268 (2014) https://doi.org/10.1093/jac/dku290
Elucidation of Cellular Mechanisms Involved in Experimental Paromomycin Resistance in Leishmania donovani
Vasundhra Bhandari, Shyam Sundar, Jean Claude Dujardin and Poonam Salotra Antimicrobial Agents and Chemotherapy 58(5) 2580 (2014) https://doi.org/10.1128/AAC.01574-13
Natural product based leads to fight against leishmaniasis
Nisha Singh, Bhuwan B. Mishra, Surabhi Bajpai, Rakesh K. Singh and Vinod K. Tiwari Bioorganic & Medicinal Chemistry 22(1) 18 (2014) https://doi.org/10.1016/j.bmc.2013.11.048
Fruitful Decade for Antileishmanial Compounds from 2002 to Late 2011
The stepwise selection for ketoconazole resistance induces upregulation of C14-demethylase (CYP51) in Leishmania amazonensis
Valter Viana Andrade-Neto, Herbert Leonel de Matos-Guedes, Daniel Cláudio de Oliveira Gomes, et al. Memórias do Instituto Oswaldo Cruz 107(3) 416 (2012) https://doi.org/10.1590/S0074-02762012000300018
Experimental Induction of Paromomycin Resistance in Antimony-Resistant Strains of L. donovani: Outcome Dependent on In Vitro Selection Protocol
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Developments in the treatment of visceral leishmaniasis
Margriet Leontine den Boer, Jorge Alvar, Robert N Davidson, Koert Ritmeijer and Manica Balasegaram Expert Opinion on Emerging Drugs 14(3) 395 (2009) https://doi.org/10.1517/14728210903153862
Paromomycin
Robert N. Davidson, Margriet den Boer and Koert Ritmeijer Transactions of the Royal Society of Tropical Medicine and Hygiene 103(7) 653 (2009) https://doi.org/10.1016/j.trstmh.2008.09.008
Paromomycin: Uptake and resistance in Leishmania donovani
Anupam Jhingran, Bhavna Chawla, Shailendra Saxena, Michael Peter Barrett and Rentala Madhubala Molecular and Biochemical Parasitology 164(2) 111 (2009) https://doi.org/10.1016/j.molbiopara.2008.12.007
Wirkstoffe zur Behandlung von Leishmaniosen. Antimon und mehr